{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:46Z","timestamp":1789506166561,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"26","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,14]]},"DOI":"10.1038\/s41388-026-03828-3","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:30:41Z","timestamp":1780115441000},"page":"2579-2595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1"],"prefix":"10.1038","volume":"45","author":[{"given":"Mayao","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-3412","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanpeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuance","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-7697","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"3828_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3828_CR2","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365\u201380.","journal-title":"Transl Androl Urol"},{"key":"3828_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/iju.14406","volume":"28","author":"M Sugiura","year":"2021","unstructured":"Sugiura M, Sato H, Kanesaka M, Imamura Y, Sakamoto S, Ichikawa T, et al. Epigenetic modifications in prostate cancer. Int J Urol. 2021;28:140\u20139.","journal-title":"Int J Urol"},{"key":"3828_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers9010009","volume":"9","author":"V Cucchiara","year":"2017","unstructured":"Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017;9:9.","journal-title":"Cancers (Basel)"},{"key":"3828_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.gene.2017.06.056","volume":"627","author":"E Froimchuk","year":"2017","unstructured":"Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene. 2017;627:337\u201342.","journal-title":"Gene"},{"key":"3828_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1242\/dev.132688","volume":"143","author":"SY Ang","year":"2016","unstructured":"Ang SY, Uebersohn A, Spencer CI, Huang Y, Lee JE, Ge K, et al. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation. Development. 2016;143:810\u201321.","journal-title":"Development"},{"key":"3828_CR7","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1093\/nar\/gkw105","volume":"44","author":"F Oswald","year":"2016","unstructured":"Oswald F, Rodriguez P, Giaimo BD, Antonello ZA, Mira L, Mittler G, et al. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res. 2016;44:4703\u201320.","journal-title":"Nucleic Acids Res"},{"key":"3828_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aah6893","volume":"355","author":"E Toska","year":"2017","unstructured":"Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017;355:1324\u201330.","journal-title":"Science"},{"key":"3828_CR9","doi-asserted-by":"publisher","first-page":"BSR20211148","DOI":"10.1042\/BSR20211148","volume":"41","author":"L Pang","year":"2021","unstructured":"Pang L, Tian H, Gao X, Wang W, Wang X, Zhang Z. KMT2D deficiency disturbs the proliferation and cell cycle activity of dental epithelial cell line (LS8) partially via Wnt signaling. Biosci Rep. 2021;41:BSR20211148.","journal-title":"Biosci Rep"},{"key":"3828_CR10","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/0008-5472.CAN-19-2247","volume":"80","author":"R Saffie","year":"2020","unstructured":"Saffie R, Zhou N, Rolland D, Onder O, Basrur V, Campbell S, et al. FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells. Cancer Res. 2020;80:2498\u2013511.","journal-title":"Cancer Res"},{"key":"3828_CR11","doi-asserted-by":"publisher","first-page":"963689721102752","DOI":"10.1177\/09636897211027521","volume":"30","author":"M Li","year":"2021","unstructured":"Li M, Shi M, Xu Y, Qiu J, Lv Q. Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer. Cell Transpl. 2021;30:9636897211027521.","journal-title":"Cell Transpl"},{"key":"3828_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108924","volume":"115","author":"P Sun","year":"2019","unstructured":"Sun P, Wu T, Sun X, Cui Z, Zhang H, Xia Q, et al. KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. Biomed Pharmacother. 2019;115:108924.","journal-title":"Biomed Pharmacother"},{"key":"3828_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2020.03.005","volume":"37","author":"H Alam","year":"2020","unstructured":"Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, et al. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell. 2020;37:599\u2013617 e597.","journal-title":"Cancer Cell"},{"key":"3828_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2022.11.015","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan Y, Han H, Hu H, Wang H, Song Y, Hao Y, et al. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell. 2023;41:88\u2013105 e108.","journal-title":"Cancer Cell"},{"key":"3828_CR15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","volume":"37","author":"S Lv","year":"2018","unstructured":"Lv S, Ji L, Chen B, Liu S, Lei C, Liu X, et al. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene. 2018;37:1354\u201368.","journal-title":"Oncogene"},{"key":"3828_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1080\/15592294.2019.1634985","volume":"14","author":"S Lv","year":"2019","unstructured":"Lv S, Wen H, Shan X, Li J, Wu Y, Yu X, et al. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics. 2019;14:1194\u2013208.","journal-title":"Epigenetics"},{"key":"3828_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41422-019-0203-2","volume":"29","author":"S Gao","year":"2019","unstructured":"Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, et al. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 2019;29:770\u20132.","journal-title":"Cell Res"},{"key":"3828_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27:1250\u201361.","journal-title":"Nat Med"},{"key":"3828_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2019.00445","volume":"10","author":"R Huang","year":"2019","unstructured":"Huang R, Grishagin I, Wang Y, Zhao T, Greene J, Obenauer JC, et al. The NCATS BioPlanet - An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics. Front Pharm. 2019;10:445.","journal-title":"Front Pharm"},{"key":"3828_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"3828_CR21","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47:W212\u2013W224.","journal-title":"Nucleic Acids Res"},{"key":"3828_CR22","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46:D380\u2013D386.","journal-title":"Nucleic Acids Res"},{"key":"3828_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s43018-024-00820-2","volume":"5","author":"B Dong","year":"2024","unstructured":"Dong B, Xu JY, Huang Y, Guo J, Dong Q, Wang Y, et al. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers. Nat Cancer. 2024;5:1427\u201347.","journal-title":"Nat Cancer"},{"key":"3828_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239\u201343.","journal-title":"Nature"},{"key":"3828_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng.3523","volume":"48","author":"T Whitington","year":"2016","unstructured":"Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, et al. Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat Genet. 2016;48:387\u201397.","journal-title":"Nat Genet"},{"key":"3828_CR26","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41588-024-01893-6","volume":"56","author":"A Parolia","year":"2024","unstructured":"Parolia A, Eyunni S, Verma BK, Young E, Liu Y, Liu L, et al. NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nat Genet. 2024;56:2132\u201343.","journal-title":"Nat Genet"},{"key":"3828_CR27","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u201397.","journal-title":"Nucleic Acids Res"},{"key":"3828_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther. 2024;9:332.","journal-title":"Signal Transduct Target Ther"},{"key":"3828_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","journal-title":"Signal Transduct Target Ther"},{"key":"3828_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48:491\u2013507.","journal-title":"Mol Cell"},{"key":"3828_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18632\/oncotarget.27988","volume":"12","author":"SS Dhar","year":"2021","unstructured":"Dhar SS, Lee MG. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget. 2021;12:1296\u2013308.","journal-title":"Oncotarget"},{"key":"3828_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107831","volume":"26","author":"RM Sanghrajka","year":"2023","unstructured":"Sanghrajka RM, Koche R, Medrano H, El Nagar S, Stephen DN, Lao Z, et al. KMT2D suppresses Sonic hedgehog-driven medulloblastoma progression and metastasis. iScience. 2023;26:107831.","journal-title":"iScience"},{"key":"3828_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108293","volume":"33","author":"M Maitituoheti","year":"2020","unstructured":"Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, et al. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep. 2020;33:108293.","journal-title":"Cell Rep"},{"key":"3828_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00432-018-2625-5","volume":"144","author":"A Abudureheman","year":"2018","unstructured":"Abudureheman A, Ainiwaer J, Hou Z, Niyaz M, Turghun A, Hasim A, et al. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2018;144:1025\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3828_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23721","volume":"35","author":"Q Li","year":"2021","unstructured":"Li Q, Wu R, Wu F, Chen Q. KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing. J Clin Lab Anal. 2021;35:e23721.","journal-title":"J Clin Lab Anal"},{"key":"3828_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"key":"3828_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019;37:288\u201395.","journal-title":"World J Mens Health"},{"key":"3828_CR38","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.21037\/tau-20-1339","volume":"10","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021;10:3104\u201316.","journal-title":"Transl Androl Urol"},{"key":"3828_CR39","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","volume":"9","author":"C Cai","year":"2014","unstructured":"Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014;9:1618\u201327.","journal-title":"Cell Rep"},{"key":"3828_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","volume":"52","author":"S Gao","year":"2020","unstructured":"Gao S, Chen S, Han D, Wang Z, Li M, Han W, et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020;52:1011\u20137.","journal-title":"Nat Genet"},{"key":"3828_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","volume":"12","author":"M Teng","year":"2021","unstructured":"Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021;12:29\u201338.","journal-title":"Protein Cell"},{"key":"3828_CR42","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI122367","volume":"129","author":"B Song","year":"2019","unstructured":"Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, et al. Targeting FOXA1-mediated repression of TGF-beta signaling suppresses castration-resistant prostate cancer progression. J Clin Invest. 2019;129:569\u201382.","journal-title":"J Clin Invest"},{"key":"3828_CR43","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","volume":"83","author":"M Li","year":"2023","unstructured":"Li M, Liu M, Han W, Wang Z, Han D, Patalano S, et al. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Res. 2023;83:1684\u201398.","journal-title":"Cancer Res"},{"key":"3828_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185\u201396.","journal-title":"Br J Cancer"},{"key":"3828_CR45","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.3390\/nu14224932","volume":"14","author":"CY Hwang","year":"2022","unstructured":"Hwang CY, Choe W, Yoon KS, Ha J, Kim SS, Yeo EJ, et al. Molecular Mechanisms for Ketone Body Metabolism, Signaling Functions, and Therapeutic Potential in Cancer. Nutrients. 2022;14:4932.","journal-title":"Nutrients"},{"key":"3828_CR46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/gutjnl-2017-315690","volume":"68","author":"M Koutsioumpa","year":"2019","unstructured":"Koutsioumpa M, Hatziapostolou M, Polytarchou C, Tolosa EJ, Almada LL, Mahurkar-Joshi S, et al. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming. Gut. 2019;68:1271\u201386.","journal-title":"Gut"},{"key":"3828_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152464","volume":"215","author":"S Wan","year":"2019","unstructured":"Wan S, Xi M, Zhao HB, Hua W, Liu YL, Zhou YL, et al. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer. Pathol Res Pr. 2019;215:152464.","journal-title":"Pathol Res Pr"},{"key":"3828_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molmet.2019.06.026","volume":"33","author":"DD Weber","year":"2020","unstructured":"Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab. 2020;33:102\u201321.","journal-title":"Mol Metab"},{"key":"3828_CR49","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1038\/s41388-021-02008-9","volume":"40","author":"E Labanca","year":"2021","unstructured":"Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, et al. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021;40:6284\u201398.","journal-title":"Oncogene"},{"key":"3828_CR50","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1074\/mcp.M112.023887","volume":"12","author":"P Saraon","year":"2013","unstructured":"Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteom. 2013;12:1589\u2013601.","journal-title":"Mol Cell Proteom"},{"key":"3828_CR51","doi-asserted-by":"publisher","first-page":"62131","DOI":"10.18632\/oncotarget.19100","volume":"8","author":"VM Morozov","year":"2017","unstructured":"Morozov VM, Li Y, Clowers MM, Ishov AM. Inhibitor of H3K27 demethylase JMJD3\/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget. 2017;8:62131\u201342.","journal-title":"Oncotarget"},{"key":"3828_CR52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.molcel.2017.06.028","volume":"67","author":"SP Wang","year":"2017","unstructured":"Wang SP, Tang Z, Chen CW, Shimada M, Koche RP, Wang LH, et al. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Mol Cell. 2017;67:308\u2013321 e306.","journal-title":"Mol Cell"},{"key":"3828_CR53","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41556-024-01446-3","volume":"26","author":"M Seehawer","year":"2024","unstructured":"Seehawer M, Li Z, Nishida J, Foidart P, Reiter AH, Rojas-Jimenez E, et al. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3. Nat Cell Biol. 2024;26:1165\u201375.","journal-title":"Nat Cell Biol"},{"key":"3828_CR54","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41586-021-03903-7","volume":"597","author":"B Shi","year":"2021","unstructured":"Shi B, Li W, Song Y, Wang Z, Ju R, Ulman A, et al. UTX condensation underlies its tumour-suppressive activity. Nature. 2021;597:726\u201331.","journal-title":"Nature"},{"key":"3828_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25:59\u201373.","journal-title":"Nat Rev Cancer"},{"key":"3828_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03828-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03828-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03828-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:02:21Z","timestamp":1782165741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03828-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":56,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026,7,14]]}},"alternative-id":["3828"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03828-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7812403\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal study protocols involving mouse experiments were approved by the Ethics Committee of Ganzhou Hospital, Southern Medical University, Southern Hospital (Approval No. TY-DKY2023-020-01). The PDTF collection was approved by the Ethics Committee of Nanfang Hospital (Approval No. NFEC-2022-299). Informed consent was obtained from all participants involved in the study. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}